Reply to Çınar et al. Comment on "Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58 , 874".

A very encouraging recent report by Borgogna et al. has shown that patients with hematological malignancies that have recovered from COVID-19 can develop a robust humoral response after vaccination [[5]]. To our knowledge, until now there are only a few publications that have reported recurrence or exacerbation of hematological malignancies in patients that underwent mRNA vaccines for COVID-19 [[6]]. From the beginning, the COVID-19 outbreak has challenged the management of patients diagnosed with hematological malignancies, due to the complex interconnections between an unknown viral infection and a dysfunctional immune system. [Extracted from the article]